@marklewismd @NEJM @MSKCancerCenter I-SPY2 showed MHC-II expression to be predictive of response to immunotherapy for breast cancer patients. This combined with studies with melanoma suggest it may be a better pan-cancer biomarker. https://t.co/6M6H5eo2Z
Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti–PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer. https://t.co/CBqBQtyAZi. #AACRtii21 https://t.co/X2HRObcPGs
Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti-PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer https://t.co/mWw4VYn5ln
Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti–PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer https://t.co/PZPG7KIUhp
RT @NatRevClinOncol: Levels of MHC-II on tumour cells are predictive of a pCR to durvalumab or pembrolizumab + NAC (ROC AUC, 0.71 (P = 0.01…
RT @NatRevClinOncol: Levels of MHC-II on tumour cells are predictive of a pCR to durvalumab or pembrolizumab + NAC (ROC AUC, 0.71 (P = 0.01…
RT @NatRevClinOncol: Levels of MHC-II on tumour cells are predictive of a pCR to durvalumab or pembrolizumab + NAC (ROC AUC, 0.71 (P = 0.01…
Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti–PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer | Clinical Cancer Research https://t.co/K9yRPajtKj
RT @NatRevClinOncol: Levels of MHC-II on tumour cells are predictive of a pCR to durvalumab or pembrolizumab + NAC (ROC AUC, 0.71 (P = 0.01…
RT @NatRevClinOncol: Levels of MHC-II on tumour cells are predictive of a pCR to durvalumab or pembrolizumab + NAC (ROC AUC, 0.71 (P = 0.01…
Levels of MHC-II on tumour cells are predictive of a pCR to durvalumab or pembrolizumab + NAC (ROC AUC, 0.71 (P = 0.01) & 0.73 (P = 0.001), respectively), but not NAC alone (AUC 0.5; P = 0.99) in pts with TNBC/HER2-negative #breastcancer: https://t.co/
Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti–PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer https://t.co/Pp2SctlDYe
RT @CCR_AACR: Predictive #biomarkers to identify #BreastCancer patients benefiting from #immunotherapies targeting PD-1/L1 are lacking. Go…
Would love to see the validation of this in KEYNOTE522 @Merck - for the patients of whom many will be treated, but only 10-15% benefit #breastcancer #bcsm #TNBC #immunotherapy
RT @CCR_AACR: Predictive #biomarkers to identify #BreastCancer patients benefiting from #immunotherapies targeting PD-1/L1 are lacking. Go…
RT @CCR_AACR: Predictive #biomarkers to identify #BreastCancer patients benefiting from #immunotherapies targeting PD-1/L1 are lacking. Go…
Predictive #biomarkers to identify #BreastCancer patients benefiting from #immunotherapies targeting PD-1/L1 are lacking. Gonzalez-Ericsson et al show that MHC-II expression on tumor cells is a predictor of anti-PD-1/L1 benefit. https://t.co/VToUOEksfy @M
RT @MammaryCell: Published in @CCR_AACR! Led by Paula Gonzalez-Ericsson, @GeorgeMasonU & @VUmedicine investigators tested the ability of M…
Published in @CCR_AACR! Led by Paula Gonzalez-Ericsson, @GeorgeMasonU & @VUmedicine investigators tested the ability of MHC-II expression on tumor cells, to predict immunotherapy-specific benefit in the neoadjuvant #BreastCancer setting. https://t.c
https://t.co/6Y3PSfGPYP Here is the study link!
RT @BalkoLab: https://t.co/6Y3PSfYqQn The impact here is high - but we need to validate in P3RCT and include as an integrated marker going…
Tumor-specific major histocompatibility-II expression predicts benefit to anti-PD-1/L1 therapy in patients with HER2-negative primary breast cancer https://t.co/myOERg3rQT
New article: Tumor-specific major histocompatibility-II expression predicts benefit to anti-PD-1/L1 therapy in patients with HER2-negative primary breast cancer https://t.co/bccTXid4Rl #melanoma #oncology https://t.co/6Hfq77sNmn
RT @PTarantinoMD: Relevant to today’s news, a new analysis from #ISPY2 - just published on @CCR_AACR - finds that eBC expressing MHC-II (~…
RT @PTarantinoMD: Relevant to today’s news, a new analysis from #ISPY2 - just published on @CCR_AACR - finds that eBC expressing MHC-II (~…
RT @PTarantinoMD: Relevant to today’s news, a new analysis from #ISPY2 - just published on @CCR_AACR - finds that eBC expressing MHC-II (~…
RT @PTarantinoMD: Relevant to today’s news, a new analysis from #ISPY2 - just published on @CCR_AACR - finds that eBC expressing MHC-II (~…
Tumor-specific major histocompatibility-II expression predicts benefit to anti-PD-1/L1 therapy in patients with HER2-negative primary breast cancer https://t.co/h2XqqL8ors
RT @PTarantinoMD: Relevant to today’s news, a new analysis from #ISPY2 - just published on @CCR_AACR - finds that eBC expressing MHC-II (~…
RT @BalkoLab: https://t.co/6Y3PSfYqQn The impact here is high - but we need to validate in P3RCT and include as an integrated marker going…
RT @PTarantinoMD: Relevant to today’s news, a new analysis from #ISPY2 - just published on @CCR_AACR - finds that eBC expressing MHC-II (~…
RT @PTarantinoMD: Relevant to today’s news, a new analysis from #ISPY2 - just published on @CCR_AACR - finds that eBC expressing MHC-II (~…
RT @PTarantinoMD: Relevant to today’s news, a new analysis from #ISPY2 - just published on @CCR_AACR - finds that eBC expressing MHC-II (~…
https://t.co/6Y3PSfYqQn The impact here is high - but we need to validate in P3RCT and include as an integrated marker going forward. This is a straightforward marker that we have done CLIA before in melanoma trials.#bcsm